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ABSTRACT 
Point of present examination work was attempted to figure bilayer tablets of lornoxicam through its joining of oral measurements 
frame that can release lornoxicam promptly in addition maintained sustained release of lornoxicam for 24 hrs to improve oral 
bioavailability of lornoxicam. Primary target of this work was plan of bilayer tablets utilizing superdisintegrant Kyron 314 for smart 
discharge layer Polyox 303 for supporting discharge layer made out of two unique classes of medications by utilizing straight 
forward simple to-scale-up definition system. The in vitro dissolution study of the prepared bilayer tablets showed a controlled 
release of active drugs over a period of 24 hours 
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INTRODUCTION 
Oral route is the most commonly employed route of drug 
administration. Although different Route of 
administration are used for the delivery of drugs, oral 
route remain the preferred mode. The popularity of the 
oral route is attributed patient acceptance, ease of 
administration, accurate dosing, cost effective 
manufacturing method and generally improved shelf-life 
of the product. Even for sustained release systems the 
oral route of administration has been investigated the 
most, because of flexibility in dosage forms design that 
the oral route offers. With many drugs, the basic goal of 
therapy is to achieve a steady-state blood level or tissue 
level that is therapeutically effective and non-toxic for 
an extended period of time.
1, 2, 3
 
Bi-layer tablet concept has long been utilized to develop 
sustained released formulation. Such tablet has a fast 
releasing layer and may contain one (bi-layer), to sustain 
the drug release. The pharmacokinetic advantage relies 
on the criterion that, drug release from the fast releasing 
layer leads to a sudden rise in the blood concentration. 
However the blood level is maintained at steady state as 
the release from sustaining layer.
4, 5, 6
 
Lornoxicam, a congener of tenoxicam, is a novel 
NSAID belonging to the oxicam group5 with extremely 
potent anti-inflammatory and analgesic activities 
7, 8
. It is 
widely used for the symptomatic treatment of pain and 
inflammation in patients with rheumatoid arthritis and 
osteoarthritis 
9
 
Bi-layer tablet is sensible for dynamic passage of two 
medicines in mix, separate two contradicting substances 
other than for kept up discharge tablet in which one 
layer is energetic discharge as beginning estimations 
second layer is reinforce estimation. This bilayer 
approach is a convenient method. Hence it makes 
possible to formulate sustained release preparations with 
the immediate release quantity in one layer and the slow 
release portion will disintegrate rapidly after ingestion 
thus providing the Initial dose of medication for 
immediate onset of action, where as the another layer in 
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the matrix layer remain intact during most of the time of 
its passage through the intestine, While dissolving 
slowly (sustained manner) from its exposed faces in this 
passage, which helps to maintain the blood level initially 
reached. 
METHODOLOGY 
 Preformulation study
10
:  
Organoleptic Characteristics of Lornoxicam 
Physical examine was done to check Organoleptic 
Characteristics of LORNOXICAM like odor. 
Solubility study of Lornoxicam
 
This study done using different solvents like water, 
ethanol, methanol, DCM, DMSO. 
Preparation of Calibration Curve for Lornoxicam: 
100 mg of pure lornoxicam was dissolved in 100 ml of 
pH 6.8 phosphate buffer. 1 ml of this solution was 
pipette out in separate 10ml volumetric flask diluted 
suitable media subjected to UV scanning in range 200-
400 nm using double beam UV-visible 
spectrophotometer. 
Preparation of 0.1N HCL: It was prepared by diluting 
8.33 ml of concentrated HCL with 1000 ml with distilled 
water. 
Preparation of Phosphate Buffer 6.8 pH: 2.38 gm of 
disodium hydrogen phosphate, 0.19gm of potassium 
dihydrogen phosphate8gm of Nacl were dissolved in 
water volume up to 1000ml. Adjust pH. 
Preparation of Standard solution (100µg/ml): 100mg 
of lornoxicam was dissolved in ethanol make up 100ml 
6.8 phosphate buffer.1ml of solution was pipette out in 
separate volumetric flask diluted it up to 10 ml with 
phosphate buffer 6.8 to produce 100µg/ml.  
From standard solution of lornoxicam, aliquots of 0.1, 
0.2, 0.3, 0.4, 0.5, 0.6, 0.70.8 were withdrawn 
subsequently diluted up to 10 ml with phosphate buffer 
of pH 6.8 to obtain series of dilutions containing 10, 20, 
30, 40, 50, 60, 70, 80 μg/ml solution. Absorbance of 
these solutions was measured UV-Visible 
Spectrophotometer at 260 nm using phosphate buffer of 
pH 6.8 as blank. 
Drug–excipients compatibility Studies by FTIR 
Spectroscopy
11
 
IR spectroscopy will conducted using FTIR 
Spectrophotometer spectrum was recorded in 
wavelength region of400–4000 cm-1. Procedure 
consisted of dispersing sample drug alone mixture of 
drug polymer in KBr compressing into discs by applying 
pressure of 5 t for 5 min in hydraulic press. Pellet was 
placed in light path spectrum was recorded. 
 
 
 
Preparation of Lornoxicam Bilayer Tablets: 
Method of preparation of Sustained Release Layer
12
 
Lornoxicam sustain release layer had been formulated 
by utilizing direct compression procedure. Weighed 
quantities of desired weighed of solid medicament other 
excipients like MCC, Retardant polymer were mixed 
properly shifted from sieve no 40. Before compression 
add talc, magnesium stearate mixed it well. Prepared 
powder blended than punched by using single punch 
tablet compression machine. 
Table 1: Composition of Lornoxicam Sustained Release 
Layer Tablet (1 TABLET) 
Tablet composition Weight (mg) 
Lornoxicam 8 
Retardant material 25-75 % 
MCC 37 
Talc 3 
Magnesium Stearate 2 
Total 150 
 
Method of Preparation of Immediate release Layer 
Lornoxicam Orodispersible layer were prepared by 
using direct compression method. Desired quantities 
already weighed material and other excipients like 
MCC, superdisintegrant, aspartame, agent were mixed 
properly shifted from sieve no 40. Before compression 
add talc, magnesium stearate mixed it well. Prepared 
powder blended than punched by using single punch 
tablet compression machine. 
Drug Content Uniformity
12, 13
 
Ten Tablets were finely powdered and an amount 
equivalent to 40 mg of Lornoxicam was accurately 
weighed and transferred to a 100 ml volumetric flask. 
Then 70ml methanol was added. The flask was shaken 
for 10 minutes. Finally, the volume was made up to the 
mark with methanol. The mixture was then filtered and 1 
ml of the filtrate was suitably diluted with methanol to 
obtain a solution containing about 40 μg ml-1 of 
Lornoxicam and analyzed for Lornoxicam content at 260 
nm using a double beam UV/Visible and methanol as a 
blank. 
In-vitro Drug Release Study of Ketoprofen Bilayer 
Tablets:  
Release of Lornoxicam was determined using a USP, six 
stage dissolution rate test apparatus- I at 50 rpm. The 
dissolution was studied using 900 mL of simulated 
intestinal fluid (without enzyme pH 6.8). The 
temperature was maintained at 37±0.5
0
C. The sample 
(5ml) was withdrawn at different time intervals 
i.e.1,2,3,4,5,6,7,8,9,10,11,12 hrs filter through whatman 
filter paper and replaced by an equal volume of 
dissolution medium sample were suitably diluted and 
analyzed for Lornoxicam content at 376 nm. 
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RESULT AND DISCUSSION 
Preformulation Study for Lornoxicam: 
Preformulation parameters, for example, Organoleptic 
trademark study, Melting Point Determination, 
dissolvability study Wavelength (λmax) Determination, 
Calibration bend, Identification of Drug by Lornoxicam, 
DSC study FT-IR study was completed. This 
incorporates different Preformulation thinks about for 
present examination work result talks about underneath 
each parameter. 
Organoleptic Characteristics of Lornoxicam 
Table 1: Organoleptic Characteristics of Lornoxicam 
PARAMETER OBSERVED RESULT 
Color Yellow White  powder 
Odor slightly unctuous with faint  
Appearance Yellow  crystalline powder 
 
Shade of Lornoxicam was imagined yellow with 
marginally unctuous or with weak trademark smell 
having yellow crystalline powder appearance as 
appeared in Table 13. 
Preparation of Calibration Curve for Lornoxicam 
Absorbance was examined between 200 to 400 nm and 
λmax was found 376 nm. 
 
 
Figure 1: Calibration curve of Lornoxicam in phosphate 
buffer 
Adjustment bend for Lornoxicam was gotten by 
utilizing 0-25 µg/mL arrangement of Lornoxicam in 
Phosphate cradle pH 7.4. Absorbance was measured at 
376 nm. Adjustment bend for Lornoxicam was appeared 
in figure 5.3. Absorbance acquired for given focuses 
was appeared in Table 18. Alignment bend indicates 
relapse condition Y= 0.0387xR2value 0.999. Result 
uncovered that medication focus between 0 – 25 µg/mL 
takes after Beer Lambert's law as relapse coefficient was 
0.999.
 
Solubility study of Lornoxicam 
Table 3: Solubility of Lornoxicam 
S. N. Solvents 
Solubility (mg/mL) 
(Mean ± S.D.) (n = 3) 
Interpretation 
1. Water 0.022±0.021 Very Slightly soluble 
2. Ethanol 1.13±0.94 Slightly soluble 
3. Methanol 4.33±0.56 Partially soluble 
4. DCM 5.94±0.98 Partially soluble 
5. Methanol: DCM 9.45±0.32 Freely soluble 
6. DMSO 3.72±0.09 Slightly soluble 
 
 Identification of Lornoxicam by FT-IR Spectroscopy 
Potassium bromide IR circle was readied utilizing 1mg of Lornoxicam on Hydraulic Pellet press checked in locale of 
4000-400 cm-1. Gotten IR Spectrum was contrasted reference range of Lornoxicam. 
 
Figure 2:  Identification of Lornoxicam by IR Spectrum 
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Figure 2 shows IR spectrum of Lornoxicam. All major 
peaks of Lornoxicam drug was observed at wave 
numbers 3417 (2 aromatic N – H stretching vibrations) 
1637 (Aromatic C = O stretching vibrations), 1082 (S = 
O stretching), 3059 (C- H aromatic), 1539 (C=C 
aromatic), 1327 (C- N) 621 (C- Cl) were observed which 
confirms identity purity of drug. 
 
Drug- Excipients Compatibility Studies by FT-IR 
 
Figure 3: FT-IR Spectrum Formulation ((Lornoxicam + Eudragit RS 100 + Ethyl Cellulose + HPMC K 4 +MCC+ 
Cross povidone+ Aspartame+ Kyron 314)  
Figure 3 show IR range of Lornoxicam medication with 
all excipients which utilized as part of definition having 
trademark assimilation band in taking after district. IR 
range of standard medication Lornoxicam, Ethyl 
cellulose, HPMC K4M, HPMC K 15, HPMC K100, 
Eudragit RS 100, Chitosan plan demonstrates same top, 
utilitarian gathering at various recurrence. Results 
uncovered no progressions found in IR tops of 
Lornoxicam, when blended with polymers. These 
perceptions show similarity of polymers with 
Lornoxicam.  
FTIR Spectroscopy was utilized to study conceivable 
association between unadulterated Lornoxicam with 
different fixings in patch plan. There was no huge 
distinction in FTIR spectra of unadulterated medication, 
physical blend detailing. All significant crests of 
Lornoxicam was seen at wave numbers 3417 (2 sweet-
smelling extending vibrations) 1637 (fragrant C=O 
extending vibrations) 1082 (S =O extending vibrations), 
1327 (C - N extending), 621 (C-Cl twisting), 3059 (C-H 
(aromatic) Stretching1539 (C = C extending) were held 
in physical blends Patch which unmistakably 
demonstrate that no cooperation exists between 
immaculate meditation all fixing.  
Trademark tops of medication show up in spectra of 
blend of medication excipients same wave number, 
demonstrating no adjustment or communication amongst 
medication excipients. From that it can infer that 
medication has kept up its personality without losing its 
trademark properties. 
Preliminary Selection of Type of retardant Material 
for Lornoxicam sustained Release layer: 
Table 4: Preliminary Selection of Type of Retardant 
Material for Lornoxicam sustained Release layer. 
Batch 
Type of retardant 
material 
Concentration of 
Retardant material 
LSB1 Ethyl Cellulose 50 
LSB2 HPMC K4M 50 
LSB3 HPMC K100M 50 
LSB4 Eudragit 50 
LSB5 Polyox WSR 303 50 
 
Characterization of Preliminary trial Batches (LSB1-LSB5) 
 
Figure 4: Effect of type of retardant material (Blue-% Drug Content, Orange-% CDR) 
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Managed discharge drug conveyance framework 
required polymers which having property to supported 
arrival of residue when it is fused into detailing. 
Retardant polymer, for example, HPMC, Chitosan, 
Eudragit, Polyox soon are utilized as part of 
pharmaceutical plan to support medication discharge. 
Nonetheless, centralization of retardant polymer in 
managed discharge tablets must be ideal. Here, Polyox 
303 has been observed to be extremely powerful 
retardant polymer for managed discharge tablet 
delivered by different strategies. Retardant polymer 
having property of swelling gelling by which they 
controls arrival of medication from detailing. Actually, 
viability of Polyox 303 in managing medication 
discharge is such that it even controls medication 
discharge without meddling with medication content. 
Indeed, even retardant polymer like HPMC eudragit has 
been used for diminishing medication discharge from 
tablet. Henceforth, LSB3, LSB4LSB 5 have been 
chosen as enhanced bunches.
 
 
Preliminary Selection of Concentration of Retardant 
Material: 
Table 5: Preliminary Selection of Concentration of 
Retardant Martial on Lornoxicam sustained Release layer. 
Batch 
Type of retardant 
material 
Concentration of 
Retardant material 
LSB6 HPMC K100M 25 
LSB7 HPMC K100M 50 
LSB8 HPMC K100M 75 
LSB9 HPMC K100M 100 
LSB10 Eudragit 25 
LSB11 Eudragit 50 
LSB12 Eudragit 75 
LSB13 Eudragit 100 
LSB14 Polyox WSR 303 25 
LSB15 Polyox WSR 303 50 
LSB16 Polyox WSR 303 75 
LSB17 Polyox WSR 303 100 
 
Characterization of Concentration of Retardant Material: 
 
Figure 5: Effect of concentration of retardant material 
As retardant material is essential prerequisite for plan of 
managed discharge detailing. To improve support 
discharge, detailing require high centralization of 
retardant material. According to preparatory trial groups, 
as convergence of retardant material increment, 
supporting arrival of medication increment. In this way, 
100 mg of retardant material chose as most extreme 
focus for detailing of managed discharge layer.
 
Preliminary Trial Batches for Orodispersible Layer: 
Preliminary Selection of Type of Super Disintegrants: 
Table 6: Preliminary Selection of Type of Super Disintegrants on Lornoxicam Orodispersible layer 
Batch Type of Super Disintegrants Concentration of Super Disintegrants 
LOB1 Sodium Starch Glycolate 10 
LOB2 Cross Povidone 10 
LOB3 Cross Carmalose Sodium 10 
LOB4 Kyron 314 10 
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Characterization of Trial batches (LOB1- LOB4) 
 
Figure 61: Effect of type of superdisintegrant (Blue-% 
Drug Content, Orange-% CDR) 
 
Orodispersible medication conveyance framework 
required super disintegrant which is having property to 
fast arrival of medication when it is joined intoplan. 
Super disintegrants, for example, Sodium starch 
glycolate, cross povidone, cross Carmalose sodium, 
Kyron 314 are utilized as part of pharmaceutical 
definition for prompt medication discharge. Be that as it 
may, grouping of super disintegrants in prompt 
discharge tablets must be ideal. Here, Kyron 314 has 
been observed to be extremely powerful super 
disintegrants for immediate discharge tablet delivered by 
different techniques. Super disintegrants having property 
of pore framing higher water absorptivity by which they 
expand arrival of medication from detailing. Indeed, 
even super disintegrants like cross povidone, cross 
Carmalose sodium have been used for upgrade 
medication discharge from tablet. Consequently, LOB2, 
LOB3LOB5 have been chosen as advanced groups. 
In-vitro disintegration Study
 
In-vitro disintegration study is important to identify 
disintegration time. As fast tablet disintegrate, gives 
faster release. 
 
Figure 7: In-vitro disintegration study 
Preliminary Selection of Concentration of Super 
Disintegrants: 
As super disintegrants is main need for preparation of 
sustained release dosage form. To increase quick release, 
preparation requires optimum amount of super 
disintegration. Acoording to primary trial batches, as 
concentration of super disintegrants enhance, release of 
drug increase. So, 10 percent of super disintegrants 
selected as optimum concentration for formulation of 
Orodispersible layer. 
Table 7: Preliminary Selection of Concentration of 
Super Disintegrants on Lornoxicam Orodispersible layer 
Batch 
Type of Super 
Disintegrants 
Concentration of 
Super Disintegrants 
(%) 
LOB5 Cross Povidone 2 
LOB6 Cross Povidone 5 
LOB7 Cross Povidone 7 
LOB8 Cross Povidone 10 
LOB9 Cross Carmalose Sod 2 
LOB10 Cross Carmalose Sod 5 
LOB11 Cross Carmalose Sod 7 
LOB12 Cross Carmalose Sod 10 
LOB13 Kyron 314 2 
LOB14 Kyron 314 5 
LOB15 Kyron 314 7 
LOB16 Kyron 314 10 
 
 
Figure 8: Effect of concentration of retardant material 
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In-vitro disintegration Study 
In vitro disintegration effect is significant to know disintegration time. As fast tablet disintegrate, gives faster release.
  
 
Figure 9: In-vitro disintegration study 
 
CONCLUSION 
Present investigation was finished to develop bilayer 
tablet of LORNOXICAM using superdisintegrant Kyron 
314 for snappy release layer Polyox 303 for supporting 
release layer. Tablets exhibited fundamental burst 
release to give stacking estimation of pharmaceutical 
took after by kept up release up to 24 hrs. This balanced 
release bilayer tablets moreover diminished dosing 
repeat, manufacture bioavailability give better patient 
consistence.  
Bi-layer tablet is upgraded valuable development to 
vanquish obstruction of single layered tablet. It is proper 
for progressive entry of medicines for bolstered release 
tablet in which one layer is snappy release as starting 
dose second layer is upkeep estimations. Course of 
action of tablets as multi layers is used to offer 
structures to association of meds, which are opposite to 
give controlled release tablet game plans by giving 
incorporating or various swelling layers.
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